Impact of Mirabegron on Erectile Function in BPH Patients
NCT ID: NCT04503850
Last Updated: 2020-08-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2020-10-01
2021-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study
NCT03600766
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
NCT02656173
A Study of Tadalafil in Benign Prostatic Hyperplasia
NCT01183650
Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH
NCT05834270
The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score
NCT00540891
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A Mirabegron
50 patients receiving Mirabegron 50 mg once daily \& alpha blocker
Mirabegron 50 MG
Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
Group B alpha blocker only
50 patients receiving alpha blocker only
Alpha Blockers
Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mirabegron 50 MG
Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
Alpha Blockers
Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* neurologic abnormality
* Any indication for prostatectomy
* abnormal bladder contractility i.e diabetics
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasr El Aini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samer Morsy
Urology Consultant
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cairo University Hospitals
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.